Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
-
Clinical Trial Information
Trial Contact: Carlo, Charlene S; Monserrate, Francheska; Mondragon, Diana; Flores-Vega, Mariangelis; Melendez, Thomas L
Trial Phone: 321.841.1324 ; 321-841-4717 ; 3218419454 ; 321-841-717 ; 321.841.6813
-
IRB No: S23.260.12
Protocol Abbrev: KINECT_DCP
Principal Investigator: Vikram Shivkumar, MD
Phase: Drug: Phase III
Age Group: Adult
Secondary Protocol No: NBI-98854-DCP3018
Treatment: Valbenazine
Therapies Involved: Medication
ClinicalTrials.gov ID: NCT05206513
-
Objective
The primary objective for this study is to evaluate the efficacy of valbenazine versus placebo on improving chorea in subjects aged 6 to 70 years who have DCP with choreiform movements.
-
Key Eligibility
Medically confirmed diagnosis of Dyskinesia due to cerebral palsy with choreiform movements. Adult subjects 18 to 70 years of age.
